Breaking News, Financial News

Minghui Pharmaceutical Announces $131 Million Pre-IPO Financing 

Financing will help advance the late-stage pipeline and global expansion.

By: Rachel Klemovitch

Assistant Editor

Minghui Pharmaceutical (Minghui), a late-stage clinical biopharmaceutical company, announced the closing of a $131 million Pre-IPO financing round led by new investor OrbiMed and co-led by Qiming Venture Partners.  Further support came from existing investor TF Capital, as well as seven new investors, including BioTrack Capital, 5Y Capital, New Day Fund, and Wider Link Enterprise Investment Limited. Representatives from OrbiMed and Qiming Venture Partners will join the company’s board o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters